Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

440

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

440 results for “Side effects”

Learn how ShareScore rates datasets ↗
zenodo48/100

SIDER Side Effect Resource

<p>Unwanted side effects of drugs are a burden on patients and a severe impediment in the development of new drugs. At the same time, adverse drug reactions (ADRs) recorded during clinical trials are an important source of human phenotypic data. It is therefore essential to combine data on drugs, targets and side effects into a more complete picture of the therapeutic mechanism of actions of drugs and the ways in which they cause adverse reactions. To this end, we have created the SIDER (&lsquo;Side Effect Resource&rsquo;,&nbsp;<a href="http://sideeffects.embl.de/">http://sideeffects.embl.de</a>) database of drugs and ADRs. The current release, SIDER 4, contains data on 1430 drugs, 5880 ADRs and 140&nbsp;064 drug&ndash;ADR pairs, which is an increase of 40% compared to the previous version. For more fine-grained analyses, we extracted the frequency with which side effects occur from the package inserts. This information is available for 39% of drug&ndash;ADR pairs, 19% of which can be compared to the frequency under placebo treatment. SIDER furthermore contains a data set of drug indications, extracted from the package inserts using Natural Language Processing. These drug indications are used to reduce the rate of false positives by identifying medical terms that do not correspond to ADRs.</p>

opencc-by-4.0Oct 2015View details →
zenodo44/100

Resources for Mitigating Chemotherapy Side Effects through Targeted Gamma-Ray Delivery and CNNs

<p>This repository includes datasets and code used in the study "Mitigating Chemotherapy Side Effects through Targeted Gamma-Ray Delivery and Convolutional Neural Networks." The resources comprise:<br>- Binding Affinity Data: Used for simulations.<br>- Brain Tumor MRI and Chest CT Scan Datasets: Used for model training.<br>- Lightweight Deep CNN: Code for building and testing models.</p>

opencc-by-4.0Nov 2024View details →
zenodo40/100

Bottom of DR1 tank, the sides of the module are fitted with glass panels which allow natural light from a window to enter the tank, and the observer to view the behaviour of the broodstock. This device ensures easy viewing and checking of the broodstock, facilitates management of feeding and allows effective monitoring of reproduction. in Reproduction of Zingel asper (Linnaeus, 1758) in controlled conditions: an assessment of the experiences realized since 2005 at the Besançon Natural History Museum

Bottom of DR1 tank, the sides of the module are fitted with glass panels which allow natural light from a window to enter the tank, and the observer to view the behaviour of the broodstock. This device ensures easy viewing and checking of the broodstock, facilitates management of feeding and allows effective monitoring of reproduction.

opencc-by-4.0Feb 2019View details →
zenodo40/100

Final project report: The Side Effects of Forced Online Distance Education (FODE)

<p>The outbreak of COVID-19 forced most universities into distance education. Three didacticians and researchers from the University of Maribor, Slovenia: Kosta Dolenc, Mateja Ploj Virtič and Andrej &Scaron;orgo formed a self-initiated initiative project group during the COVID-19 epidemic and started the project with the working title: The Side Effects of Forced Online Distance Education (FODE). The aim of the project, was to investigate the response of university teachers and students to the new situation.</p>

opencc-by-4.0Nov 2021View details →
zenodo40/100

Sempa et al. 2019 - A Retrospective audit of treatment outcomes, side-effect profiles and default and mortality rates of HIV/AIDS patients at the antiretroviral clinic at Pretoria Academic Hospital.

<p>The comprehensive demographic and long-term treatment data of the first, consecutive, 963 patients older than 18 years of age who presented for ART at the Tshwane District Hospital in Gauteng, South Africa during 2004 and 2005 were selected for analysis. All patients started ART after 2004 as part of the South African national HIV treatment plan and were treated according to the National Department of Health HIV guidelines (2004) operative at the time, i.e. eligibility for ART was CD4 &lt;200 cells/&micro;L or WHO stage 4 disease regardless of CD4 count. Treatment was initiated using a standardized triple-drug regimen consisting of two nucleoside reverse transcriptase inhibitors, mostly d4T and 3TC, and one non-nucleoside reverse transcriptase inhibitor, either NVP or EFV. CD4 and HIV-1 VL monitoring was performed at treatment initiation &lsquo;baseline&rsquo; and then 6-monthly, according to the national protocol. Demographic, anthropometric, clinical, ART and 5-year longitudinal treatment response data were collected. Excluded all second-line ART visits for all patients who were switched to second-line therapy.</p>

opencc-by-4.0May 2019View details →
zenodo40/100

Screening for side effects of COVID-19 drug candidates on cardiovascular development -RAW DATA qPCR RESULTS

<p>Raw Data relating to Figures 4 and Supplemental Figures S7 and S8 of the article&nbsp;</p> <p><strong>Screening for side effects of COVID-19 drug candidates on cardiovascular development </strong></p> <p>Alexander Ernst<sup>1#</sup>, Indre Piragyte<sup>1,2#</sup>, Ayisha Marwa MP<sup>1,2</sup>, Ngoc Dung Le<sup>3</sup>, Denis Grandgirard<sup>3</sup>, Stephen L. Leib<sup>3</sup>, Andrew Oates<sup>4</sup>, Nadia Mercader<sup>1,2,5</sup></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><sup>1</sup> Institute of Anatomy, University of Bern, Switzerland</p> <p><sup>2</sup> Department for Biomedical Research DBMR, University of Bern, Switzerland</p> <p><sup>3</sup> Institute for Infectious Diseases, University of Bern, Switzerland</p> <p><sup>4 </sup>School of Life Sciences, &Eacute;cole polytechnique f&eacute;d&eacute;rale de Lausanne, Switzerland</p> <p><sup>5</sup> Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain</p> <p># shared first-authorship</p>

opencc-by-4.0Dec 2022View details →
zenodo40/100

The impact of pharmaceutical form and simulated side effects in an open-label-placebo RCT for improving psychological distress in highly stressed students (Open Data and Open Materials)

<p>&nbsp; Open-label placebo (OLP) may be utilized to reduce psychological distress. Yet, potential contextual effects have not been explored. We investigated the impact of pharmaceutical form and the simulation of side effects in a parallel group RCT (DRKS00030987). A sample of 177 highly stressed university students at risk of depression were randomly assigned by computer generated tables to a one-week intervention with active or passive OLP nasal spray or passive OLP capsule or a no-treatment control group. After the intervention, groups differed significantly in depressive symptoms but not regarding other outcomes of psychological distress (stress, anxiety, sleep quality, somatization), well-being or treatment expectation. OLP groups benefitted significantly more compared to the no-treatment control group (<em>d</em>=.40), OLP nasal spray groups significantly more than the OLP capsule group (<em>d</em>=.40) and the active OLP group significantly more than the passive OLP groups (<em>d</em>=.42). Interestingly, before intervention, most participants, regardless of group assignment, believed that the OLP capsule would be most beneficial. The effectiveness of OLP treatments seems to be highly influenced by the symptom focus conveyed by the OLP rationale. Moreover, pharmaceutical form and simulation of side effects may modulate efficacy, while explicit treatment expectation seems to play a minor role.</p>

opencc-by-4.0Dec 2022View details →
zenodo36/100

Dataset for article: Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects

Open the record for dataset details and reuse information.

opencc-by-4.0Dec 2024View details →
zenodo36/100

DataSet: Framing side effects positively: a way to enhance analgesia?

<p>Side effects are frequent in pharmacological pain management, potentially preceding analgesia and limiting drug tolerability. Discussing side effects is part of informed consent, yet can favor nocebo effects. This study aimed to test whether a positive suggestion regarding side effects, which could act as reminders of the medication having been absorbed, might favor analgesia in a clinical interaction model.</p> <p>&nbsp;</p> <p>Sixty-six healthy males participated in a study &ldquo;to validate pupillometry as an objective measure of analgesia&rdquo;. Participants were unknowingly randomized double-blind to positive vs control information about side effects embedded in a video regarding the study drugs. Sequences of moderately painful heat stimuli applied before and after treatment with diclofenac and atropine served to evaluate analgesia. Atropine was deceptively presented as a co-analgesic, but used to induce side effects. Adverse events (AE) were collected with the General Assessment of Side Effects (GASE) questionnaire prior to the second induced pain sequence. Debriefing fully informed participants regarding the purpose of the study and showed them the two videos.</p> <p>&nbsp;</p> <p>The combination of medication led to significant analgesia, without a between-group difference. Positive information about side effects increased the attribution of AE to the treatment compared to the control information. The total GASE score was correlated with analgesia, i.e., the more AEs reported, the stronger the analgesia. Interestingly, there was a significant between-groups difference on this correlation: the GASE score and analgesia correlated only in the positive information group. This provides evidence for a selective link between AEs and pain relief in the group who received the suggestion that AEs could be taken as a sign &ldquo;that help was on the way&rdquo;. During debriefing, 65% of participants said they would prefer to receive the positive message in a clinical context. These results suggest feasibility and validity to investigate such a framing of side effects in a clinical context, for example in patients with chronic pain.</p>

opencc-by-4.0Jul 2018View details →
zenodo36/100

Supplementary material: High and hyper: is serotonin to blame for fentanyl-induced psychomotor side-effects in pigs?

<p>Supplementary material for article paper&nbsp;High and hyper: is serotonin to blame for fentanyl-induced psychomotor side-effects in pigs?&nbsp;&nbsp;</p>

opencc-by-4.0Apr 2023View details →
zenodo36/100

Table 2. Studies on psychiatric side effects of fluoroquinolones. The risk of bias and study quality assessed with the Effective Public Health Practice Project's Quality Assessment Tool for Quantitative Studies (QATQS) was presented as the global rating for each publication (3 – weak).

<p>Studies on psychiatric side effects of fluoroquinolones. The risk of bias and study quality assessed with the Effective Public Health Practice Project&rsquo;s Quality Assessment Tool for Quantitative Studies (QATQS) was presented as the global rating for each publication (3 &ndash; weak).</p>

opencc-by-4.0Jun 2023View details →
ClinicalTrials.gov36/100

Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

ClinicalTrials.gov study NCT00345033. IPD Sharing: Not stated. Countries: 1. Publications: 7.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Side Effects of Atropine (SEA) Study

ClinicalTrials.gov study NCT03593044. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

ClinicalTrials.gov study NCT01867710. IPD Sharing: Not stated. Countries: 4. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space("ICE PLS")

ClinicalTrials.gov study NCT00747916. IPD Sharing: Not stated. Countries: 1. Publications: 9.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

ClinicalTrials.gov study NCT00566852. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

ClinicalTrials.gov study NCT00754468. IPD Sharing: Not stated. Countries: 1. Publications: 9.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

ClinicalTrials.gov study NCT02076997. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

ClinicalTrials.gov study NCT05831176. IPD Sharing: YES. Countries: 4. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

ClinicalTrials.gov study NCT01336140. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record